Now that an FDA science board has received findings from a panel concluding that the FDA's original safety assessment on bisphenol A was flawed, the review will be forwarded to FDA Director Dr. Andrew von Eschenbach. The FDA has until February to respond.

Full Story:
TIME magazine

Related Summaries